Immune Pharmaceuticals Inc (NASDAQ:IMNP) CEO Daniel Gedeon Teper bought 42,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 26th. The stock was purchased at an average price of $0.59 per share, for a total transaction of $24,780.00. Following the transaction, the chief executive officer now owns 4,810,905 shares of the company’s stock, valued at $2,838,433.95. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Daniel Gedeon Teper also recently made the following trade(s):

  • On Tuesday, January 19th, Daniel Gedeon Teper purchased 44,200 shares of Immune Pharmaceuticals stock. The stock was bought at an average cost of $0.57 per share, with a total value of $25,194.00.
  • On Tuesday, January 12th, Daniel Gedeon Teper purchased 39,400 shares of Immune Pharmaceuticals stock. The stock was bought at an average cost of $0.62 per share, with a total value of $24,428.00.

Immune Pharmaceuticals Inc (NASDAQ:IMNP) opened at 0.4801 on Friday. The stock’s 50 day moving average price is $0.67 and its 200 day moving average price is $1.19. Immune Pharmaceuticals Inc has a 52 week low of $0.48 and a 52 week high of $2.28. The firm’s market capitalization is $14.54 million.

Immune Pharmaceuticals (NASDAQ:IMNP) last announced its quarterly earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by $0.17. On average, equities analysts expect that Immune Pharmaceuticals Inc will post ($0.63) EPS for the current year.

A number of brokerages have issued reports on IMNP. FBR & Co. reissued an “outperform” rating on shares of Immune Pharmaceuticals in a report on Friday, October 30th. Chardan Capital boosted their price target on Immune Pharmaceuticals from $5.00 to $6.50 and gave the company a “buy” rating in a report on Tuesday, October 13th. Finally, Roth Capital began coverage on Immune Pharmaceuticals in a report on Thursday, October 8th. They issued a “buy” rating and a $6.00 price target for the company.

Immune Pharmaceuticals Inc. is a United States-based clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics, including monoclonal antibodies, nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. Its pipeline includes, Bertilimumab, which is a clinical-stage human antibody, targeting eotaxin-1, which is involved in a number of immune mediated diseases; NanomAbs, which is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells, and AmiKet, which is a topical neuropathic pain drug candidate. The Company’s oncology pipeline includes Crolibulin, which is a small molecule vascular disrupting agent and apoptosis inducer for the intended treatment of patients with solid tumors, and Azixa, which is a vascular disruptive agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement.

12 Month Chart for NASDAQ:IMNP

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Immune Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.